



Multi-centric real-world effectiveness of mepolizumab in severe chronic rhinosinusitis with nasal polyps in Germany

Severe uncontrolled CRSwNP




Mepolizumab 100mg s.c. every 4 weeks



6-30 months follow-up after treatment initiation

Improved significantly 6 months after treatment initiation



VAS


Patient reported outcome measures



Sniffin' sticks score




Nasal polyp score



Mepolizumab use showed sustained improvement of nasal symptoms



Comorbid asthma was associated with increased improvement of nasal symptoms



Switching from a different biological to mepolizumab was associated with reduced improvement